tiprankstipranks
Trending News
More News >
Boston Scientific (BSX)
NYSE:BSX
US Market

Boston Scientific (BSX) Stock Forecast & Price Target

Compare
4,145 Followers
See the Price Targets and Ratings of:

BSX Analyst Ratings

Strong Buy
21Ratings
Strong Buy
21 Buy
0 Hold
0 Sell
Based on 21 analysts giving stock ratings to
Boston
Scientific
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BSX Stock 12 Month Forecast

Average Price Target

$106.80
▲(55.80% Upside)
Based on 21 Wall Street analysts offering 12 month price targets for Boston Scientific in the last 3 months. The average price target is $106.80 with a high forecast of $124.00 and a low forecast of $94.00. The average price target represents a 55.80% change from the last price of $68.55.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"75":"$75","100":"$100","125":"$125","87.5":"$87.5","112.5":"$112.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":124,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$124.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":106.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$106.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":94,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$94.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[75,87.5,100,112.5,125],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,76.22,79.89538461538461,83.57076923076923,87.24615384615385,90.92153846153846,94.59692307692308,98.27230769230769,101.94769230769231,105.62307692307692,109.29846153846154,112.97384615384615,116.64923076923077,120.32461538461538,{"y":124,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,76.22,78.57230769230769,80.92461538461538,83.27692307692308,85.62923076923077,87.98153846153846,90.33384615384615,92.68615384615384,95.03846153846153,97.39076923076922,99.74307692307693,102.09538461538462,104.44769230769231,{"y":106.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,76.22,77.58769230769231,78.95538461538462,80.32307692307693,81.69076923076923,83.05846153846154,84.42615384615385,85.79384615384615,87.16153846153846,88.52923076923076,89.89692307692307,91.26461538461538,92.63230769230769,{"y":94,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":103.79,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.24,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.19,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.17,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.78,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.41,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.66,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 71,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.85,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 88,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.72,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 80,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.01,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 61,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.35,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.87,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 74,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.22,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 67,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$124.00Average Price Target$106.80Lowest Price Target$94.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi
$102$94
Buy
37.13%
Upside
Assigned
03/12/26
Boston Scientific price target lowered to $94 from $102 at CitiBoston Scientific price target lowered to $94 from $102 at Citi
Morgan Stanley Analyst forecast on BSX
Morgan Stanley
Morgan Stanley
$118
Buy
72.14%
Upside
Reiterated
03/11/26
Morgan Stanley Sticks to Its Buy Rating for Boston Scientific (BSX)
TD Cowen
$100
Buy
45.88%
Upside
Reiterated
03/09/26
Boston Scientific (BSX): CHAMPION AF Trial Poised to Strengthen Watchman Evidence, Broaden Adoption, and Support Buy Rating
UBS
$120
Buy
75.05%
Upside
Reiterated
03/05/26
UBS Sticks to Their Buy Rating for Boston Scientific (BSX)
Bank of America Securities Analyst forecast on BSX
Bank of America Securities
Bank of America Securities
$105
Buy
53.17%
Upside
Reiterated
03/03/26
Boston Scientific: Near-Term EP Reset but 2027 Growth Drivers Support Buy Rating
BTIG
$110
Buy
60.47%
Upside
Reiterated
02/20/26
BTIG Reaffirms Their Buy Rating on Boston Scientific (BSX)
Needham
$97
Buy
41.50%
Upside
Reiterated
02/18/26
Boston Scientific: BUY on WATCHMAN Growth Optionality and Favorable CHAMPION-AF Risk/Reward Setup
Canaccord Genuity Analyst forecast on BSX
Canaccord Genuity
Canaccord Genuity
$112$109
Buy
59.01%
Upside
Reiterated
02/17/26
Boston Scientific price target lowered to $109 from $112 at CanaccordBoston Scientific price target lowered to $109 from $112 at Canaccord
J.P. Morgan Analyst forecast on BSX
J.P. Morgan
J.P. Morgan
Buy
Reiterated
02/16/26
Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX), Neurocrine (NASDAQ: NBIX) and Dexcom (NASDAQ: DXCM)
Barclays Analyst forecast on BSX
Barclays
Barclays
$124
Buy
80.89%
Upside
Reiterated
02/12/26
Barclays Reaffirms Their Buy Rating on Boston Scientific (BSX)
Stifel Nicolaus Analyst forecast on BSX
Stifel Nicolaus
Stifel Nicolaus
$110
Buy
60.47%
Upside
Reiterated
02/12/26
Analysts Offer Insights on Healthcare Companies: Soligenix (NASDAQ: SNGX) and Boston Scientific (NYSE: BSX)
Truist Financial Analyst forecast on BSX
Truist Financial
Truist Financial
$120$95
Buy
38.58%
Upside
Reiterated
02/05/26
Analysts Conflicted on These Healthcare Names: Eli Lilly & Co (NYSE: LLY), McKesson (NYSE: MCK) and Boston Scientific (NYSE: BSX)
Mizuho Securities Analyst forecast on BSX
Mizuho Securities
Mizuho Securities
$140$115
Buy
67.76%
Upside
Reiterated
02/05/26
Boston Scientific price target lowered to $115 from $140 at MizuhoBoston Scientific price target lowered to $115 from $140 at Mizuho
Robert W. Baird Analyst forecast on BSX
Robert W. Baird
Robert W. Baird
$118$101
Buy
47.34%
Upside
Reiterated
02/05/26
Boston Scientific price target lowered to $101 from $118 at BairdBoston Scientific price target lowered to $101 from $118 at Baird
Wells Fargo Analyst forecast on BSX
Wells Fargo
Wells Fargo
$125$94
Buy
37.13%
Upside
Reiterated
02/05/26
Wells Fargo Sticks to Its Buy Rating for Boston Scientific (BSX)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi
$102$94
Buy
37.13%
Upside
Assigned
03/12/26
Boston Scientific price target lowered to $94 from $102 at CitiBoston Scientific price target lowered to $94 from $102 at Citi
Morgan Stanley Analyst forecast on BSX
Morgan Stanley
Morgan Stanley
$118
Buy
72.14%
Upside
Reiterated
03/11/26
Morgan Stanley Sticks to Its Buy Rating for Boston Scientific (BSX)
TD Cowen
$100
Buy
45.88%
Upside
Reiterated
03/09/26
Boston Scientific (BSX): CHAMPION AF Trial Poised to Strengthen Watchman Evidence, Broaden Adoption, and Support Buy Rating
UBS
$120
Buy
75.05%
Upside
Reiterated
03/05/26
UBS Sticks to Their Buy Rating for Boston Scientific (BSX)
Bank of America Securities Analyst forecast on BSX
Bank of America Securities
Bank of America Securities
$105
Buy
53.17%
Upside
Reiterated
03/03/26
Boston Scientific: Near-Term EP Reset but 2027 Growth Drivers Support Buy Rating
BTIG
$110
Buy
60.47%
Upside
Reiterated
02/20/26
BTIG Reaffirms Their Buy Rating on Boston Scientific (BSX)
Needham
$97
Buy
41.50%
Upside
Reiterated
02/18/26
Boston Scientific: BUY on WATCHMAN Growth Optionality and Favorable CHAMPION-AF Risk/Reward Setup
Canaccord Genuity Analyst forecast on BSX
Canaccord Genuity
Canaccord Genuity
$112$109
Buy
59.01%
Upside
Reiterated
02/17/26
Boston Scientific price target lowered to $109 from $112 at CanaccordBoston Scientific price target lowered to $109 from $112 at Canaccord
J.P. Morgan Analyst forecast on BSX
J.P. Morgan
J.P. Morgan
Buy
Reiterated
02/16/26
Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX), Neurocrine (NASDAQ: NBIX) and Dexcom (NASDAQ: DXCM)
Barclays Analyst forecast on BSX
Barclays
Barclays
$124
Buy
80.89%
Upside
Reiterated
02/12/26
Barclays Reaffirms Their Buy Rating on Boston Scientific (BSX)
Stifel Nicolaus Analyst forecast on BSX
Stifel Nicolaus
Stifel Nicolaus
$110
Buy
60.47%
Upside
Reiterated
02/12/26
Analysts Offer Insights on Healthcare Companies: Soligenix (NASDAQ: SNGX) and Boston Scientific (NYSE: BSX)
Truist Financial Analyst forecast on BSX
Truist Financial
Truist Financial
$120$95
Buy
38.58%
Upside
Reiterated
02/05/26
Analysts Conflicted on These Healthcare Names: Eli Lilly & Co (NYSE: LLY), McKesson (NYSE: MCK) and Boston Scientific (NYSE: BSX)
Mizuho Securities Analyst forecast on BSX
Mizuho Securities
Mizuho Securities
$140$115
Buy
67.76%
Upside
Reiterated
02/05/26
Boston Scientific price target lowered to $115 from $140 at MizuhoBoston Scientific price target lowered to $115 from $140 at Mizuho
Robert W. Baird Analyst forecast on BSX
Robert W. Baird
Robert W. Baird
$118$101
Buy
47.34%
Upside
Reiterated
02/05/26
Boston Scientific price target lowered to $101 from $118 at BairdBoston Scientific price target lowered to $101 from $118 at Baird
Wells Fargo Analyst forecast on BSX
Wells Fargo
Wells Fargo
$125$94
Buy
37.13%
Upside
Reiterated
02/05/26
Wells Fargo Sticks to Its Buy Rating for Boston Scientific (BSX)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Boston Scientific

3 Months
xxx
Success Rate
18/24 ratings generated profit
75%
Average Return
+5.54%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +5.54% per trade.
1 Year
Jayson BedfordRaymond James
Success Rate
41/54 ratings generated profit
76%
Average Return
+14.72%
reiterated a buy rating 6 months ago
Copying Jayson Bedford's trades and holding each position for 1 Year would result in 75.93% of your transactions generating a profit, with an average return of +14.72% per trade.
2 Years
xxx
Success Rate
43/54 ratings generated profit
80%
Average Return
+29.52%
reiterated a xxx
rating 6 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 79.63% of your transactions generating a profit, with an average return of +29.52% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BSX Analyst Recommendation Trends

Rating
Nov 25
Dec 25
Jan 26
Feb 26
Mar 26
Strong Buy
0
0
1
5
6
Buy
80
61
38
69
61
Hold
2
2
4
18
18
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
82
63
43
92
85
In the current month, BSX has received 67 Buy Ratings, 18 Hold Ratings, and 0 Sell Ratings. BSX average Analyst price target in the past 3 months is 106.80.
Each month's total comprises the sum of three months' worth of ratings.

BSX Financial Forecast

BSX Earnings Forecast

Next quarter’s earnings estimate for BSX is $0.79 with a range of $0.78 to $0.85. The previous quarter’s EPS was $0.80. BSX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year BSX has Performed in-line its overall industry.
Next quarter’s earnings estimate for BSX is $0.79 with a range of $0.78 to $0.85. The previous quarter’s EPS was $0.80. BSX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year BSX has Performed in-line its overall industry.

BSX Sales Forecast

Next quarter’s sales forecast for BSX is $5.18B with a range of $5.08B to $5.28B. The previous quarter’s sales results were $5.29B. BSX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year BSX has Performed in-line its overall industry.
Next quarter’s sales forecast for BSX is $5.18B with a range of $5.08B to $5.28B. The previous quarter’s sales results were $5.29B. BSX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year BSX has Performed in-line its overall industry.

BSX Stock Forecast FAQ

What is BSX’s average 12-month price target, according to analysts?
Based on analyst ratings, Boston Scientific’s 12-month average price target is 106.80.
    What is BSX’s upside potential, based on the analysts’ average price target?
    Boston Scientific has 55.80% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BSX a Buy, Sell or Hold?
          Boston Scientific has a consensus rating of Strong Buy which is based on 21 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Boston Scientific’s price target?
            The average price target for Boston Scientific is 106.80. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $124.00 ,the lowest forecast is $94.00. The average price target represents 55.80% Increase from the current price of $68.55.
              What do analysts say about Boston Scientific?
              Boston Scientific’s analyst rating consensus is a Strong Buy. This is based on the ratings of 21 Wall Streets Analysts.
                How can I buy shares of BSX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.